IMPORTANCE Nutritional uptake of lutein, zeaxanthin, and ω-3 polyunsaturated fatty acids may increase macular pigment optical density (MPOD) and thereby protect against the development of age-related macular degeneration (AMD).
A ge-related macular degeneration (AMD) leads to photoreceptor degeneration of the macula and to loss of central vision. The role of antioxidants in preventing the onset of macular damage was demonstrated in the interventional Age-Related Eye Disease Study (AREDS), 1 which showed that dietary supplementation with antioxidants (vitamin C, vitamin E, and beta carotene) and oligo-elements (zinc) may slow the evolution of some forms of AMD. Macular pigment protects the macula from photooxidation through its light-screening capacity and its antioxidant activity. Lutein and zeaxanthin are the main components of macular pigment. These 2 xanthophylls have a protective role against retinal oxidation through the absorption of damaging blue light, neutralization of photosensitizers and reactive oxygen species, and scavenging of free radicals. 2 There is growing interest in the potential role of dietary lutein and zeaxanthin to prevent the development of AMD. A first step toward the demonstration of a preventive effect of macular pigment for AMD consists in the evaluation of the effect of lutein and zeaxanthin supplementation on plasma and retinal concentrations in individuals with AMD. Previous randomized clinical trials showed increased plasma and retinal concentrations of lutein and zeaxanthin after dietary supplementation in patients with early AMD 3 and in a population of women aged 60 to 80 years. 4 Regarding risk factors, multiple environmental and genetic risk factors may predispose to the development of AMD. The genetic component appears to explain a large proportion of risk variation, and individuals with a family history of AMD have a higher risk of developing AMD. 6, 7 Moreover, individuals with a confirmed family history of AMD have significantly lower levels of macular pigment optical density (MPOD) than individuals with no known family history of the disease. 8 Whether dietary supplements containing lutein and zeaxanthin may increase MPOD in those with high genetic risk of AMD remains unknown. Therefore, we performed a randomized clinical trial based on the hypothesis that dietary supplementation containing lutein, zeaxanthin, ω-3 polyunsaturated fatty acids, and antioxidants could increase the density of macular pigment in first-generation offspring of parents with neovascular AMD.
Methods

Study Design and Treatments
The Lutein Influence on Macula of Persons Issued From AMD Parents (LIMPIA) is a phase 3, double-blind, randomized clinical trial (clinicaltrials.gov Identifier NCT01269697) performed at 2 university hospitals in France (at Bordeaux and Dijon) from January 2011 (first participant first visit) to February 2013 (last participant last visit). It aimed to evaluate the efficacy of daily dietary supplementation with lutein, zeaxanthin, ω-3 polyunsaturated fatty acids, and antioxidants to increase MPOD through elevated concentrations of plasma lutein and zeaxanthin (trial protocol in Supplement 1). The analysis was conducted from January to November 2016.
Adult participants aged 40 to 70 years were required to have at least one parent with a history of neovascular AMD and have an Early Treatment Diabetic Retinopathy Study (ET-DRS) visual acuity of 20/25 or better. In addition, they had to remain free of any sign of late AMD for both eyes or other eye disease that would have made AMD evaluation and visual acuity measurements unlikely or difficult (ie, severe glaucoma, myopia of at least −6 diopters, or other severe retinopathy). Individuals with a history of cataract surgery or opacities preventing the evaluation of retinal photographs (cataract or corneal dystrophy) and individuals with food supplementation in the previous year or predicted to be noncompliant were excluded. The trial was conducted in compliance with the Good Clinical Practice guideline and the Declaration of Helsinki. The study protocol and questionnaires were reviewed and approved by the ethics committee of Centre Hospitalier Universitaire Bordeaux. All participants were apprised about the study and gave written informed consent.
Participants were randomized in a 1:1 ratio to receive either 2 daily dietary nutritional supplementation capsules or placebo for 6 months (M6). Each participant was treated for 6 months with capsules of a dietary supplement (2 times daily, before breakfast and lunch) containing lutein (5 mg), zeaxanthin (1 mg), vitamin C (90 mg), vitamin E (15 mg), zinc (7.5 mg), copper (<0.5 mg), and resveratrol (0.5 mg), as well as 33 mg of fish oil (Epax; Ålesund, Norway) that included 50% ω-3 (Nutrof Total; Laboratoires Théa) or a matched placebo containing paraffin provided by Laboratoires Théa. All other dietary supplements containing lutein or zeaxanthin were not allowed throughout the study. Treatments were allocated online by a clinical research associate using a centralized randomization list stratified by hospital (random block sizes of 4 and 6).
Study Evaluations
Follow-up visits were scheduled after 3 months (M3) and M6 of treatment and then during a 6-month extended follow-up period at 9 months (M9) and 12 months (M12). Standardized case report forms were used to record demographics and medical and family history at baseline (D0), including AMD phenotype. A standardized food questionnaire was administered
Key Points
Question Is macular pigment density increased with dietary supplementation containing lutein, zeaxanthin, ω-3 polyunsaturated fatty acids, and vitamins?
Findings Among 120 participants (239 eyes) in the Lutein Influence on Macula of Persons Issued From AMD Parents (LIMPIA) randomized clinical trial with a 6-month treatment period followed by a 6-month follow-up period, no increase in macular pigment optical density was observed when measured with the modified MPD-Visucam 200 (Carl Zeiss Meditec) or the modified Heidelberg Retina Angiograph (Heidelberg Engineering) in treated patients (n = 60) compared with patients receiving placebo (n = 60).
Meanings Macular pigment density may increase after dietary supplementation, but it is not measurable.
to assess previous consumption of lutein, zeaxanthin, docosahexaenoic acid, and fish oil. All participants received a complete ophthalmic examination with refraction, slitlamp biomicroscopy, and ophthalmoscopy. Lens opacity was assessed at slitlamp biomicroscopy using the Lens Opacities Classification System, version II.
9 Visual function was recorded by measuring best-corrected visual acuity and contrast sensitivity with the Pelli-Robson contrast sensitivity test. The AMD status was assessed by ophthalmoscopy, color retinal photographs, and spectral-domain optical computed tomography (SD-OCT SPECTRALIS; Heidelberg Engineering). All participants underwent MPOD measurements of both eyes at D0 and then at M3, M6, M9, and M12, first with the modified MPD-Visucam 200 (Carl Zeiss Meditec) and then the modified Heidelberg Retina Angiograph (Heidelberg Engineering) (HRA) on the same day through dilated pupils (one drop of tropicamide [0.5%] and phenylephrine hydrochloride [2.5%]) as described previously. 10 The MPOD measurements were performed at each hospital by a single examiner (M.-B.R. in Bordeaux and C.C.-G. in Dijon). Compliance was evaluated by a questionnaire and by collecting empty blister packs.
MPOD Measurements
The macular pigment density module for the MPD-Visucam 200 used the reflectance of a single 460-nm wavelength based on a single blue-reflection ophthalmoscopy image to determine MPOD and its spatial distribution. Shading was used that approximates the reflectance of the fundus in the absence of macular pigment. The MPD-Visucam 200 is based on a 3-dimensional parabolic function automatically fitted to fundus reflectance at peripheral locations. The individual was positioned in front of the ophthalmoscope and was instructed to look at a target inside. The fundus was illuminated by a monochromatic blue light. The following 4 MPOD parameters were automatically calculated: maximum optical density (MPOD measured at the peak), mean right eye (mean MPOD within the measurement area), area (area where macular pigment could be detected), and volume (sum of all optical densities) as recommended by the manufacturer (Carl Zeiss Meditec).
For HRA measurements, each participant was positioned in front of the camera and was instructed to look straight ahead. After focusing the scanning laser ophthalmoscope on the macular region, sequences of 208 images were captured at 488 nm (well absorbed) and 514 nm (minimally absorbed) at least 30 seconds after retinal bleaching as described by Trieschmann et al. 11 The MPOD maps were generated by digital subtraction of the log autofluorescence images. We recorded MPOD at 0°e ccentricity, and we located circles centered on the fovea at eccentricities of 0.50°, 1.00°, 2.00°, and 6.00°; the mean MPOD values were calculated for each using the software provided by the manufacturer of the device (Heidelberg Engineering). The MPOD was expressed in optical density units. Typical macular pigment distribution can follow 3 different patterns (with a central peak, a ringlike pattern, or a steady decline), and MPOD was in most cases optically undetectable at 6.00°e ccentricity.
Analysis of Blood Samples
Plasma lipids were analyzed at the biochemistry department of Centre Hospitalier Universitaire Bordeaux from fasting blood samples collected at baseline and M12. Plasma lutein and zeaxanthin measurements were performed at DSM Nutritional Products (Kaiseraugst, Switzerland). Plasma samples were analyzed for lutein (sum of all E isomers and Z isomers) and zeaxanthin (sum of all E isomers and Z isomers).
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Statistical Analysis
The sample size was calculated based on an expected mean MPOD of 0.36 at M6 with the HRA at 0.98°eccentricity in the placebo group, an expected increase of at least 20% (ie, difference of 0.07 U) in the group receiving lutein and zeaxanthin supplementation, and a common SD of 0.13 U.
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With a power of 80% and a 2-sided type I error of 5%, a total of 53 participants were to be recruited in each group using a 2-sample t test, assuming equal variances (proc power in SAS, version 9.1; SAS Institute Inc). Taking into account potential withdrawals, the total sample size was increased to 120 participants. Moreover, this sample size allowed sufficient power for comparison of the mean plasma lutein and zeaxanthin concentrations, assuming an expected increase of at least 30% in the experimental group compared with a hypothesized mean (SD) of approximately 192 (88) μg/L. All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc). Data were described using usual statistics, including means (SDs) and first quartile, third quartile, minimum, and maximum values for quantitative variables. Frequencies and percentages were used for qualitative or ordinal variables. Differences between treatment groups were analyzed using a linear mixed model (fixed effect) with random intercept (allowing to take into account the correlation between data of the 2 eyes for each individual) adjusted for age, sex, body mass index (BMI), smoking, and hospital. Analyses were based on the intent-to-treat principle, with missing data equaling failure (for each visit, missing values were replaced by the lowest observed value for both treatment groups combined). One-sided P < .05 was the threshold of statistical significance.
Results
A total of 120 participants (60 in each group) were included at 2 university hospitals in France (at Bordeaux and Dijon). Their mean (SD) age was 56.7 (6.6) years, and 71.7% (n = 86) were female. A total of 239 eyes were analyzed (119 in the lutein plus zeaxanthin [L + Z] group and 120 in the placebo group); one eye was excluded from analysis because of previous cataract surgery ( Figure 1 ).
Main Baseline Characteristics
The 2 groups (L + Z and placebo) did not differ by age, sex, BMI, smoking, medical history, or plasma lipid concentrations at baseline ( Table 1) . Mothers (97 of 118 participants) had AMD onset at a mean (SD) age of 78 (8) participants) had AMD onset at a mean (SD) age of 76 (8) years. Four participants (6.7%) in the L + Z group had a previous ocular history (treated glaucoma in 2 individuals). The food questionnaire showed that 15.0% (n = 9) of participants in the L + Z group and 11.7% (n = 7) of participants in the placebo group were users of vitamins or other dietary supplements. The mean (SD) lutein and zeaxanthin consumption during the previous year was 1139 (597) × 10 3 U in the L + Z group vs 949 (578) × 10 3 U in the placebo group. There were no relevant differences between the L + Z and placebo groups in ocular baseline characteristics (Table 1) . Retinophotographs were normal in approximately 75% of eyes for both groups. No reticular drusen or features of late AMD were identified in either group. Large drusen were found in 2 eyes (1.7%) in the L + Z group and in 3 eyes (2.5%) in the placebo group, and small drusen were observed in 23 eyes (19.3%) in the L + Z group and in 25 eyes (20.8%) in the placebo group. On SD-OCT, 12 of 73 eyes (16.4%) in the L + Z group and 16 of 74 eyes (21.6%) in the placebo group had classic drusen.
Evolution of Plasma Lutein and Zeaxanthin Concentrations
As summarized in Table 2 , plasma lutein and zeaxanthin concentrations were increased from 0.38 to 0.58 μmol/L for lutein and from 0.08 to 0.14 μmol/L for zeaxanthin after M3 of supplementation in the L + Z group, while no significant changes were shown in the placebo group. The plasma levels of lutein and zeaxanthin remained elevated during M6 after randomization and then decreased to baseline values at M3 after treatment discontinuation (at M9). Differences between treatment groups were statistically significant at M3 and M6.
Small but statistically significant differences were shown between groups after M3 of treatment discontinuation for lutein and after M3 and M6 of treatment discontinuation for zeaxanthin.
Macular Pigment Measurements
The MPOD measured with the modified HRA and changes in MPOD from baseline are listed for each degree of eccentricity in eTable 1 in Supplement 2. Results did not show any significant change from baseline in either treatment group for the mean MPOD within each degree of eccentricity at each visit. There was no statistically significant difference between groups.
As summarized in Figure 2 , the mean (SD) MPOD change between baseline and M6 within 0.98°eccentricity was 0.05 (0.15) in the L + Z group (observed in 108 participants) and 0.03 (0.16) in the placebo group (observed in 107 participants). With missing data equaling failure, the mean (SD) evolution was 0.01 (0.22) in the L + Z group and −0.03 (0.22) in the placebo group (Table 3) . There was no statistically significant difference between groups in MPOD variation using the unadjusted linear model or the adjusted model.
Using the modified MPD-Visucam 200, no relevant differences were shown in MPOD between the L + Z and placebo groups. These results are summarized in eTable 2 in Supplement 2.
Discussion
In this randomized clinical trial of a 6-month dietary supplementation with lutein and zeaxanthin, ω-3 polyunsaturated fatty acids, and antioxidants that included first-generation offspring of parents with neovascular AMD, intake of dietary supplementation led to a rapid and sustained increase in plasma lutein and zeaxanthin concentrations but did not translate into elevation of macular pigment density. The MPOD after lutein and zeaxanthin supplementation was measured by the modified HRA at each eccentricity (0.51°, 0.98°, 1.99°, and 6.00°) and by the reflectance methods using the modified MPD-Visucam 200.
In contrast, previous randomized controlled interventional studies using Visucam measurement or heterochromatic flicker photometry have shown that nutrient formulations containing lutein and zeaxanthin produced a statistically significant increase in macular pigment density among individuals with AMD 3, 14, 15 and in a population of older women. 4 Although the supplement formulations differed in those studies, the dosages of lutein and zeaxanthin and the duration of intervention are consistent with the LIMPIA randomized clinical trial, and the elevations of plasma lutein and zeaxanthin concentrations are similar. 4 Therefore, the absence of MPOD elevation after lutein and zeaxanthin supplementation in the LIMPIA trial cannot be due to nutrient malabsorption. It is known that MPOD responses to lutein and zeaxanthin supplementation are variable across individuals. 16 In previous investigations, 20% to 50% of relevant study participants had low plasma response, 16 In the Lutein Nutrition Effects Measured by Autofluorescence (LUNA) study, 11 among patients with AMD receiving lutein and zeaxanthin supplementation, there was an increase in plasma lutein from 0.16 mg/mL at baseline to 0.593 mg/mL concomitant with a mean MPOD increase by 16% after 6 months. Despite increased plasma lutein and zeaxanthin after dietary supplementation, a substantial proportion of participants herein did not show a detectable increase in MPOD over the 6-month study period. We believe that the absence of increased MPOD could be due to the macular saturation in a young population with virtually no risk factors for AMD besides the family history. Trieschmann et al 11 reported that the greatest increase in MPOD at 0.50°eccentricity in individuals receiving supplemental lutein and zeaxanthin was found in those with the lowest baseline MPOD. It was suggested that the mechanisms underlying retinal capture or stabilization of macular lutein and zeaxanthin may be saturable. Similarly, in a 12-month interventional study 15 among patients with nonexudative AMD, the time course of MPOD using a formulation containing lutein, zeaxanthin, and ω-3 polyunsaturated fatty acids showed a rapid increase within M3, reached a plateau after M6, and demonstrated sustained values until 1M2, consistent with a saturable mechanism.
In a young, healthy population, dietary supplementation with lutein and zeaxanthin resulted in a statistically significant (although modest) increase of 4% to 5% in MPOD after M6 (corresponding to MPOD variation from 0.44 to 0.47 U using heterochromatic flicker photometry), while no effect was shown after M3 despite statistically significant increases in plasma lutein and zeaxanthin concentrations (2.3 times and 6.3 times from baseline, respectively). 17 The rise in MPOD at M6 was only weakly related to the plasma lutein level measured at M3.
Nevertheless, the baseline mean MPOD among participants in the LIMPIA trial (0.6 U at 0.51°eccentricity) was much higher compared with studies 10, 13, 18 in other populations that included patients with AMD. Nolan et al 8 previously showed that individuals with a family history of AMD had lower MPOD compared with individuals without a family history of AMD. However, besides a family history of AMD, most of the participants in the LIMPIA trial had no risk factors that may influence the concentration of carotenoids in the retina, such as high BMI, smoking, diabetes, or dyslipidemia. 8, 16 Our study enrolled mostly women (78.3% [47 of 60] in the L + Z group), who tend to have a poorer response to lutein and zeaxanthin supplementation than men.
19 Results from the Carotenoids in Age-Related Eye Disease Study (CAREDS) 16 indicated that women with high lutein and zeaxanthin levels in their diet and plasma also had high MPOD. However, only 3% of MPOD variation was explained by lutein and zeaxanthin supplementation, and 8% of MPOD variation could be justified by dietary, lifestyle, medical, and physical variables. Abbreviations: D0, baseline; L + Z, lutein plus zeaxanthin; M3, 3 months; M6, 6 months; M9, 9 months; M12, 12 months; NA, not applicable. a Linear mixed model with random intercept on available data adjusted for age, sex, body mass index, smoking, and hospital.
Research Original Investigation Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 and Effect on Macular Pigment
Taken together, results of the LIMPIA trial suggest poor capture of plasma lutein and zeaxanthin in the macula, consistent with a young, female population without major risk factors except for a family history of neovascular AMD. Further research is necessary to identify the best method to measure macular pigment.
Limitations
Limitations of our study are related to participants who were phakic. Therefore, we cannot extrapolate MPOD measurement results in pseudophakic eyes.
Conclusions
The LIMPIA trial showed no significant difference in MPOD with lutein and zeaxanthin dietary supplementation after M6 of treatment despite increased plasma levels of lutein and zeaxanthin in first-generation offspring of parents with neovascular AMD. Additional research is needed to better evaluate macular pigment density and to understand cellular uptake and metabolism of these nutrients within the macula. What is the role of macular pigment density measures in future clinical studies of age-related macular degeneration (AMD)? Measuring and following macular pigment optical density (MPOD) in clinical studies of AMD is intriguing, given reported associations between lower values and increased odds of macular degeneration, potential mechanisms of protection, including blue light filtering and free radical neutralization, the presence of lutein and zeaxanthin in the retina, and availability of lutein and zeaxanthin supplements.
1 Studies have shown that supplementation with lutein and zeaxanthin in healthy volunteers as well as in those with early or late AMD has resulted in increases in serum concentrations of lutein and zeaxanthin and macular pigment density.
2 A post hoc secondary analysis of an AgeRelated Eye Disease Study 2 (AREDS2) subgroup with the lowest dietary intake of lutein and zeaxanthin suggests a protective effect of lutein and zeaxanthin supplementation in reducing the risk of progression to advanced AMD. 3 To my knowledge, studies have not established the value of MPOD or change in MPOD as a valid surrogate for measuring risk of progression to advanced AMD, and the optimal dose and duration of lutein and zeaxanthin supplementation remains unanswered.
In this issue of JAMA Ophthalmology, Korobelnik et al 4 report on results from the LIMPIA study, in which 120 participants with first-generation familial history of neovascular AMD were randomized between daily supplementation with 10 mg of lutein, 2 mg of zeaxanthin, 180 mg of vitamin C, 30 mg of vitamin E, 15 mg of zinc, less than 1 mg of copper, 1 mg of resveratrol, and 66 mg of fish oil or placebo for 6 months. Although statistically significant increases in plasma lutein and zeaxanthin levels (more than 2-fold increases) were detected PRIMARY OBJECTIVE To evaluate the efficacy of 6 months of food supplementation with lutein, zeaxanthin and Omegas 3 to increase the density of the macular pigment at 6 months in subjects at risk of genetic AMD (1st generation from parents affected of AMD).
SECONDARY OBJECTIVES -To evaluate the efficacy of 6 months of food supplementation with lutein, zeaxanthin and Omegas 3 to increase the plasma level of Lutein and Zeaxanthin in subjects at risk for genetic AMD (1st generation from affected parents Of AMD).
-Measure the initial density of the macular pigment by two methods: autofluorescence and reflectivity; Thanks to 2 measuring instruments (HRA and Visucam) in the center of Dijon and 3 measuring devices (HRA, Visucam and Maculux) in the center of Bordeaux, before any supplementation. -To evaluate the efficacy on the density of the macular pigment after 3 months of supplementation, by the same methods.
-To evaluate the efficacy on the density of the macular pigment after 3 and 6 months of stop for the 2 groups treated, and also for the placebo group -Assess the effect of supplementation on plasma cholesterol levels, triglycerides, lutein and zeaxanthin after 3 and 6 months of supplementation. -Measure the evolution of plasma levels of lutein and zeaxanthin, after 3 and 6 months of supplementation stop -Evaluate the correlation between pigment measurements and the clinical form of AMD in the parent (FO photos already present in our files) -Evaluate the changes of the fundus of the eye at the beginning and during the follow-up of the study (evaluated on retinophotos color and OCT Spectralis) -Evaluate the modification of the visual acuity with correction, measured at 4 meters with the ETDRS scale, and the vision of the contrasts.
-Evaluate the efficacy of supplementation on cognitive tests, after 3 and 6 months of supplementation.
-Measure the evolution of cognitive tests, after 3 and 6 months of supplementation stop. -Assess the general tolerance, -Describe the age, history of smoking, HTA (and possible treatments), height, weight, previous consumption of fatty acids (DHA in particular, with a food questionnaire on oils consumed and fish).
-Describe the AMD Phenotype of the parent (s) (followed in the service) -Describe the genetic profile in relation to the genes identified as risk factors for AMD in the subjects included.
-Measurement of plasma fatty acids to:
• To evaluate the efficacy of supplementation on plasma omega 3 levels after 3 and 6 months of supplementation • Measure the evolution of plasma levels of omega 3 fatty acids, after 3 an d 6 months of supplementation stop To evaluate the correlation between plasma levels of omega-3 fatty acids and macular pigment density 1 Si la recherche est multicentrique, indiquer le ou les noms des investigateurs coordonnateurs et le nombre total d'investigateurs. 3 Préciser dans l'ordre : le nom des auteurs, le titre de la publication, le nom de la revue, l'année, le numéro du tome, les pages concernées.
Summary of final report
before and after supplementation. Statistical analysis: The data were described using the usual statistics: mean, standard deviation (SD), first quartile (Q1), third quartile (Q3), minimum value (min), maximum value for quantitative variables and frequencies And percentages for qualitative or ordinal variables. Differences between treatment groups were analyzed using a general linear mixed model (fixed effect) with randomized interception adjusted for age, sex, body mass index (BMI), smoking and the center. The analyzes were based on the intention of processing, with the missing data = failure. Summary -research findings The average age was 56.7 years with 71.7% of women. The mother of 97 subjects (80.8%) had neovascular AMD, with only 25 of the subjects's fathers (20.8%).
-Results of the evaluation of effectiveness, if any: The blood samples taken confirmed the increase in plasma carotenoids after 3 and 6 months of follow-up in the supplementation group. In addition, serum concentrations of Lutein and Zeaxanthin are correlated with oral administration of lutein, zeaxanthin, omega-3 fatty acids and antioxidants for 6 months. Measurements of macular pigment density using either HRA-modified (Heidelberg) or Visucam 200 MPD (Carl Zeiss Meditec) did not demonstrate a significant increase in macular pigment density in the treated group Relative to the control group. -Safety assessment results, if applicable: NA -Conclusion: The LIMPIA study did not show a significant difference in MPD after oral supplementation of Lutein + Zeaxanthin after 6 months of treatment despite the increase in plasma levels of Lutein and Zeaxanthin in first generation subjects from parents with AMD . Further research is needed to better evaluate the density of macular pigments and to understand the cellular uptake and metabolism of these nutrients in the macula 
